Teva V. Lilly: Conflicting Positions at PTAB and District Court Sink Patent Challenge

Why It Matters

The ruling shows that arguments successful in PTAB IPRs can undermine later district‑court defenses, reshaping how pharma companies defend method‑of‑treatment patents. It signals that courts may favor new‑use claims when the underlying genus is well‑known, affecting future patent drafting and litigation tactics.

Key Takeaways

• Federal Circuit reversed JMOL, upholding Teva’s headache method claims.
• Court treated invention as new use of known antibody genus.
• Lilly’s own IPR arguments about obviousness backfired in district court.
• Align §112 and §103 defenses early to avoid contradictory positions.
• Method‑of‑treatment claims may satisfy written description with one representative species.

Pulse Analysis

The Federal Circuit’s reversal of the district‑court JMOL in Teva v. Lilly illustrates how patent disputes can evolve when they span the Patent Trial and Appeal Board and federal courts. In the original inter‑partes reviews, Lilly argued that Teva’s anti‑CGRP antibodies were obvious, leading the PTAB to invalidate the antibody patents under §103. Simultaneously, Teva pursued infringement litigation over method‑of‑treatment claims, a strategy that later hinged on the same “well‑known” characterization of the antibody genus. By turning Lilly’s own statements into a weapon, the appellate court affirmed that a single disclosed species can satisfy the written‑description requirement when the genus and its manipulation are established in the art.

Legal scholars note that the decision leans on the “new‑use” doctrine, which permits broader written‑description support for claims that recast a known compound for a novel therapeutic application. The court emphasized that the invention was the method of treating headache, not the antibody itself, and that routine humanization techniques rendered the disclosure adequate. This approach aligns with precedent allowing limited species disclosure when the skilled artisan can readily identify additional functional variants, a nuance especially relevant for biologics where the genotype‑phenotype relationship is well‑understood.

For life‑science companies, the case is a cautionary tale about multi‑forum coordination. Positions taken in PTAB IPRs—particularly broad “well‑known” language—can become admissions that weaken §112 defenses later. Practitioners should synchronize obviousness and written‑description arguments early, ensuring that the narrative presented to the PTAB does not contradict the strategy in district courts. By treating the patent family as a single strategic entity, firms can avoid the pitfall of today’s routine‑obviousness claim becoming tomorrow’s written‑description vulnerability.